{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T16:18:07Z","timestamp":1784305087917,"version":"3.55.0"},"reference-count":112,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["GO 565\/18\u20101"],"award-info":[{"award-number":["GO 565\/18\u20101"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.drudis.2022.05.024","type":"journal-article","created":{"date-parts":[[2022,5,30]],"date-time":"2022-05-30T18:20:38Z","timestamp":1653934838000},"page":"2497-2509","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Targeted drug delivery to the retinal pigment epithelium: Untapped therapeutic potential for retinal diseases"],"prefix":"10.1016","volume":"27","author":[{"given":"Marilena","family":"Bohley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea E.","family":"Dillinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernst R.","family":"Tamm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Achim","family":"Goepferich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2022.05.024_b0005","unstructured":"World Health Organization. Programme for the Prevention of Blindness and Deafness. Global initiative for the elimination of avoidable blindness: World Health Organization; 2000; WHO\/PBL\/97.61 Rev.2."},{"issue":"7","key":"10.1016\/j.drudis.2022.05.024_b0010","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/nrd3745","article-title":"Ophthalmic drug discovery: novel targets and mechanisms for retinal diseases and glaucoma","volume":"11","author":"Zhang","year":"2012","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"10.1016\/j.drudis.2022.05.024_b0015","doi-asserted-by":"crossref","first-page":"e022188","DOI":"10.1136\/bmjopen-2018-022188","article-title":"Global prevalence of diabetic retinopathy: Protocol for a systematic review and meta-analysis","volume":"9","author":"Cheloni","year":"2019","journal-title":"BMJ Open"},{"issue":"1","key":"10.1016\/j.drudis.2022.05.024_b0020","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s40662-016-0063-5","article-title":"Epidemiology of age-related macular degeneration (AMD): Associations with cardiovascular disease phenotypes and lipid factors","volume":"3","author":"Pennington","year":"2016","journal-title":"Eye Vision"},{"key":"10.1016\/j.drudis.2022.05.024_b0025","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2147\/EB.S94436","article-title":"Retinopathy of prematurity blindness worldwide: Phenotypes in the third epidemic","volume":"8","author":"Quinn","year":"2016","journal-title":"Eye Brain"},{"key":"10.1016\/j.drudis.2022.05.024_b0030","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ceb.2019.08.001","article-title":"Retinal pigment epithelium polarity in health and blinding diseases","volume":"62","author":"Caceres","year":"2020","journal-title":"Curr Opin Cell Biol"},{"issue":"3","key":"10.1016\/j.drudis.2022.05.024_b0035","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1152\/physrev.00021.2004","article-title":"The retinal pigment epithelium in visual function","volume":"85","author":"Strauss","year":"2005","journal-title":"Physiol Rev"},{"issue":"9","key":"10.1016\/j.drudis.2022.05.024_b0040","doi-asserted-by":"crossref","first-page":"802","DOI":"10.2174\/156652410793937813","article-title":"The Retinal Pigment Epithelium in Health and Disease","volume":"10","author":"R Sparrrow","year":"2010","journal-title":"CMM"},{"issue":"Suppl 1","key":"10.1016\/j.drudis.2022.05.024_b0045","doi-asserted-by":"crossref","first-page":"i7","DOI":"10.1136\/bjophthalmol-2013-303844","article-title":"What is the evidence for systemic effects of intravitreal anti-VEGF agents, and should we be concerned?","volume":"98","author":"Avery","year":"2014","journal-title":"British J Ophthalmol"},{"issue":"7","key":"10.1016\/j.drudis.2022.05.024_b0050","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/eye.2013.107","article-title":"Adverse events and complications associated with intravitreal injection of anti-VEGF agents: A review of literature","volume":"27","author":"Ghasemi Falavarjani","year":"2013","journal-title":"Eye"},{"issue":"6","key":"10.1016\/j.drudis.2022.05.024_b0055","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/nrd.2015.17","article-title":"Ten years of anti-vascular endothelial growth factor therapy","volume":"15","author":"Ferrara","year":"2016","journal-title":"Nat Rev Drug Discovery"},{"issue":"5","key":"10.1016\/j.drudis.2022.05.024_b0060","doi-asserted-by":"crossref","first-page":"38","DOI":"10.4103\/0976-500X.120947","article-title":"Anti-vascular endothelial growth factor drugs safety and efficacy in ophthalmic diseases","volume":"4","author":"Ventrice","year":"2013","journal-title":"J Pharmacol Pharmacother"},{"issue":"1","key":"10.1016\/j.drudis.2022.05.024_b0065","doi-asserted-by":"crossref","first-page":"4816","DOI":"10.1038\/s41598-020-61706-8","article-title":"Prevalence and new onset of depression and anxiety among participants with AMD in a European cohort","volume":"10","author":"Rezapour","year":"2020","journal-title":"Sci Rep"},{"issue":"14","key":"10.1016\/j.drudis.2022.05.024_b0070","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1056\/NEJMra062326","article-title":"Age-related macular degeneration","volume":"355","author":"de Jong","year":"2006","journal-title":"New Engl J Med"},{"issue":"24","key":"10.1016\/j.drudis.2022.05.024_b0075","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1056\/NEJMra0801537","article-title":"Age-related macular degeneration","volume":"358","author":"Jager","year":"2008","journal-title":"New Engl J Med"},{"issue":"6","key":"10.1016\/j.drudis.2022.05.024_b0080","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1006\/exer.2001.1094","article-title":"Complement activation and inflammatory processes in Drusen formation and age related macular degeneration","volume":"73","author":"Johnson","year":"2001","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.drudis.2022.05.024_b0085","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ejphar.2016.03.001","article-title":"Targeting the complement system for the management of retinal inflammatory and degenerative diseases","volume":"787","author":"Xu","year":"2016","journal-title":"Eur J Pharmacol"},{"issue":"4","key":"10.1016\/j.drudis.2022.05.024_b0090","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.mam.2012.03.007","article-title":"Complement dysregulation in AMD: RPE-Bruch\u2019s membrane-choroid","volume":"33","author":"Sparrow","year":"2012","journal-title":"Mol Aspects Med"},{"key":"10.1016\/j.drudis.2022.05.024_b0095","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.3389\/fimmu.2019.01007","article-title":"The Challenges and promise of complement therapeutics for ocular diseases","volume":"10","author":"Park","year":"2019","journal-title":"Front Immunol"},{"issue":"9827","key":"10.1016\/j.drudis.2022.05.024_b0100","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1016\/S0140-6736(12)60282-7","article-title":"Age-related macular degeneration","volume":"379","author":"Lim","year":"2012","journal-title":"The Lancet"},{"issue":"4","key":"10.1016\/j.drudis.2022.05.024_b0105","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1136\/bjo.86.4.363","article-title":"Is diabetic retinopathy an inflammatory disease?","volume":"86","author":"Adamis","year":"2002","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.drudis.2022.05.024_b0110","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.visres.2017.03.003","article-title":"Diabetic retinopathy is a neurodegenerative disorder","volume":"139","author":"Lynch","year":"2017","journal-title":"Vision Res"},{"issue":"5","key":"10.1016\/j.drudis.2022.05.024_b0115","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.preteyeres.2011.05.002","article-title":"Inflammation in diabetic retinopathy","volume":"30","author":"Tang","year":"2011","journal-title":"Progress Retinal Eye Res"},{"key":"10.1016\/j.drudis.2022.05.024_b0120","doi-asserted-by":"crossref","DOI":"10.1007\/s40618-017-0648-4","article-title":"Diabetic retinopathy: New therapeutic perspectives based on pathogenic mechanisms","author":"Hern\u00e1ndez","year":"2017","journal-title":"J Endocrinol Invest"},{"issue":"5","key":"10.1016\/j.drudis.2022.05.024_b0125","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.survophthal.2018.04.002","article-title":"Retinopathy of prematurity: A review of risk factors and their clinical significance","volume":"63","author":"Kim","year":"2018","journal-title":"Surv Ophthalmol"},{"issue":"1","key":"10.1016\/j.drudis.2022.05.024_b0130","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.ophtha.2014.07.050","article-title":"Pathophysiology and Mechanisms of Severe Retinopathy of Prematurity","volume":"122","author":"Hartnett","year":"2015","journal-title":"Ophthalmology"},{"issue":"9902","key":"10.1016\/j.drudis.2022.05.024_b0135","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1016\/S0140-6736(13)60178-6","article-title":"Retinopathy of prematurity","volume":"382","author":"Hellstrom","year":"2013","journal-title":"The Lancet"},{"issue":"1","key":"10.1016\/j.drudis.2022.05.024_b0140","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s12974-017-0943-1","article-title":"Retinopathy of prematurity: Inflammation, choroidal degeneration, and novel promising therapeutic strategies","volume":"14","author":"Rivera","year":"2017","journal-title":"J Neuroinflammat"},{"issue":"11","key":"10.1016\/j.drudis.2022.05.024_b0145","first-page":"1856","article-title":"New insight into the role of the complement in the most common types of retinopathy-current literature review","volume":"11","author":"Chrzanowska","year":"2018","journal-title":"Int J Ophthalmol"},{"issue":"Pt 3","key":"10.1016\/j.drudis.2022.05.024_b0150","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1038\/eye.2001.141","article-title":"The role of the retinal pigment epithelium: Topographical variation and ageing changes","volume":"15","author":"Boulton","year":"2001","journal-title":"Eye (London, England)"},{"issue":"8","key":"10.1016\/j.drudis.2022.05.024_b0155","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1111\/ceo.13834","article-title":"Retinal pigment epithelium and age-related macular degeneration: A review of major disease mechanisms","volume":"48","author":"Somasundaran","year":"2020","journal-title":"Clin Exp Ophthalmol"},{"key":"10.1016\/j.drudis.2022.05.024_b0160","doi-asserted-by":"crossref","first-page":"100803","DOI":"10.1016\/j.preteyeres.2019.100803","article-title":"Interactions of the choroid, Bruch\u2019s membrane, retinal pigment epithelium, and neurosensory retina collaborate to form the outer blood-retinal-barrier","volume":"76","author":"Fields","year":"2020","journal-title":"Progress Retinal Eye Res"},{"key":"10.1016\/j.drudis.2022.05.024_b0165","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.exer.2013.09.015","article-title":"Retinal pigment epithelium (RPE) cytoskeleton in vivo and in vitro","volume":"126","author":"Bonilha","year":"2014","journal-title":"Exp Eye Res"},{"issue":"16","key":"10.1016\/j.drudis.2022.05.024_b0170","doi-asserted-by":"crossref","DOI":"10.1242\/jcs.238279","article-title":"Membrane trafficking in the retinal pigment epithelium at a glance","volume":"133","author":"Storm","year":"2020","journal-title":"J Cell Sci"},{"key":"10.1016\/j.drudis.2022.05.024_b0175","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.visres.2017.05.009","article-title":"The inner blood-retinal barrier: Cellular basis and development","volume":"139","author":"D\u00edaz-Cor\u00e1nguez","year":"2017","journal-title":"Vision Res"},{"key":"10.1016\/j.drudis.2022.05.024_b0180","doi-asserted-by":"crossref","first-page":"100846","DOI":"10.1016\/j.preteyeres.2020.100846","article-title":"The cell biology of the retinal pigment epithelium","author":"Lakkaraju","year":"2020","journal-title":"Progress Retinal Eye Res"},{"key":"10.1016\/j.drudis.2022.05.024_b0185","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ejpb.2019.08.008","article-title":"Role of retinal pigment epithelium permeability in drug transfer between posterior eye segment and systemic blood circulation","volume":"143","author":"Ramsay","year":"2019","journal-title":"Eur J Pharm Biopharm"},{"issue":"2","key":"10.1016\/j.drudis.2022.05.024_b0190","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/1350-9462(96)00012-2","article-title":"Growth factors in the retina and retinal pigmented epithelium","volume":"15","author":"Campochiaro","year":"1996","journal-title":"Progress Retinal Eye Res"},{"issue":"2","key":"10.1016\/j.drudis.2022.05.024_b0195","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1350-9462(96)00028-6","article-title":"Growth factors and their receptors in the retina and pigment epithelium","volume":"16","author":"Tanihara","year":"1997","journal-title":"Progress Retinal Eye Res"},{"issue":"5","key":"10.1016\/j.drudis.2022.05.024_b0200","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1056\/NEJM200002033420511","article-title":"Pigment-epithelium-derived factor\u2014a key coordinator of retinal neuronal and vascular functions","volume":"342","author":"King","year":"2000","journal-title":"New Engl J Med"},{"issue":"5425","key":"10.1016\/j.drudis.2022.05.024_b0205","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1126\/science.285.5425.245","article-title":"Pigment epithelium-derived factor: A potent inhibitor of angiogenesis","volume":"285","author":"Dawson","year":"1999","journal-title":"Science"},{"issue":"13","key":"10.1016\/j.drudis.2022.05.024_b0210","doi-asserted-by":"crossref","first-page":"9478","DOI":"10.1167\/iovs.11-8353","article-title":"Expression and role of VEGF in the adult retinal pigment epithelium","volume":"52","author":"Ford","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"13","key":"10.1016\/j.drudis.2022.05.024_b0215","first-page":"5836","article-title":"VEGF Is Required for Neuroretina Survival and Function","volume":"49","author":"Maharaj","year":"2008","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1","key":"10.1016\/j.drudis.2022.05.024_b0220","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1350-9462(00)00017-3","article-title":"Retinal Pigment Epithelium-immune System Interactions: Cytokine Production and Cytokine-induced Changes","volume":"20","author":"Holtkamp","year":"2001","journal-title":"Progress Retinal Eye Rese"},{"key":"10.1016\/j.drudis.2022.05.024_b0225","doi-asserted-by":"crossref","first-page":"296","DOI":"10.3389\/fimmu.2012.00296","article-title":"The privileged immunity of immune privileged organs: The case of the eye","volume":"3","author":"Benhar","year":"2012","journal-title":"Front Immunol"},{"issue":"1\u20133","key":"10.1016\/j.drudis.2022.05.024_b0230","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s12026-009-8146-1","article-title":"Immune regulation in the retina","volume":"47","author":"Detrick","year":"2010","journal-title":"Immunol Res"},{"key":"10.1016\/j.drudis.2022.05.024_b0235","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.exer.2013.04.016","article-title":"Complement expression in retinal pigment epithelial cells is modulated by activated macrophages","volume":"112","author":"Luo","year":"2013","journal-title":"Exp Eye Res"},{"issue":"8","key":"10.1016\/j.drudis.2022.05.024_b0240","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/j.drudis.2019.03.004","article-title":"Drug delivery to retinal photoreceptors","volume":"24","author":"Himawan","year":"2019","journal-title":"Drug Discovery Today"},{"key":"10.1016\/j.drudis.2022.05.024_b0245","first-page":"1243","article-title":"Presence and regulation of cannabinoid receptors in human retinal pigment epithelial cells","volume":"15","author":"Wei","year":"2009","journal-title":"Mol Vision"},{"issue":"9","key":"10.1016\/j.drudis.2022.05.024_b0250","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1016\/j.drudis.2018.06.009","article-title":"Retinal pigment epithelial cells as a therapeutic tool and target against retinopathies","volume":"23","author":"Pavan","year":"2018","journal-title":"Drug Discovery Today"},{"issue":"11","key":"10.1016\/j.drudis.2022.05.024_b0255","first-page":"3555","article-title":"The P2Y(2) receptor agonist INS37217 stimulates RPE fluid transport in vitro and retinal reattachment in rat","volume":"43","author":"Maminishkis","year":"2002","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1","key":"10.1016\/j.drudis.2022.05.024_b0260","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/joim.12528","article-title":"Targeting orphan G protein-coupled receptors for the treatment of diabetes and its complications: C-peptide and GPR146","volume":"281","author":"Kolar","year":"2017","journal-title":"J Intern Med"},{"issue":"12","key":"10.1016\/j.drudis.2022.05.024_b0265","doi-asserted-by":"crossref","first-page":"21915","DOI":"10.1002\/jcp.28755","article-title":"MiR-455-5p ameliorates HG-induced apoptosis, oxidative stress and inflammatory via targeting SOCS3 in retinal pigment epithelial cells","volume":"234","author":"Chen","year":"2019","journal-title":"J Cell Physiol"},{"issue":"9","key":"10.1016\/j.drudis.2022.05.024_b0270","doi-asserted-by":"crossref","first-page":"2906","DOI":"10.1021\/acs.molpharmaceut.5b00729","article-title":"Prediction of Ocular Drug Distribution from Systemic Blood Circulation","volume":"13","author":"Vellonen","year":"2016","journal-title":"Mol Pharm"},{"issue":"14","key":"10.1016\/j.drudis.2022.05.024_b0275","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1016\/j.addr.2005.09.004","article-title":"Topical and systemic drug delivery to the posterior segments","volume":"57","author":"Hughes","year":"2005","journal-title":"Adv Drug Deliv Rev"},{"issue":"5","key":"10.1016\/j.drudis.2022.05.024_b0280","first-page":"961","article-title":"Drug delivery for posterior segment eye disease","volume":"41","author":"Geroski","year":"2000","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"5\u20136","key":"10.1016\/j.drudis.2022.05.024_b0285","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.drudis.2010.12.004","article-title":"Drug delivery to the posterior segment of the eye","volume":"16","author":"Thrimawithana","year":"2011","journal-title":"Drug Discovery Today"},{"issue":"1","key":"10.1016\/j.drudis.2022.05.024_b0290","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics13010108","article-title":"Ocular Drug Delivery to the Retina: Current Innovations and Future Perspectives","volume":"13","author":"Kim","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.drudis.2022.05.024_b0295","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.preteyeres.2016.12.001","article-title":"Pharmacokinetic aspects of retinal drug delivery","volume":"57","author":"del Amo","year":"2017","journal-title":"Progress Retinal Eye Res"},{"key":"10.1016\/j.drudis.2022.05.024_b0300","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.jconrel.2014.05.031","article-title":"Nanotherapy for posterior eye diseases","volume":"193","author":"Kaur","year":"2014","journal-title":"J Controll Release : Off J Controll Release Soc"},{"key":"10.1016\/j.drudis.2022.05.024_b0305","article-title":"Nanoparticulate Drug Delivery to the Retina","author":"Li","year":"2020","journal-title":"Mol Pharm"},{"key":"10.1016\/j.drudis.2022.05.024_b0310","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.preteyeres.2013.04.001","article-title":"Nanomedicines for back of the eye drug delivery, gene delivery, and imaging","volume":"36","author":"Kompella","year":"2013","journal-title":"Progress Retinal Eye Res"},{"issue":"1","key":"10.1016\/j.drudis.2022.05.024_b0315","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/fcp.12561","article-title":"Progress on ocular siRNA gene-silencing therapy and drug delivery systems","volume":"35","author":"Jiang","year":"2021","journal-title":"Fundam Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.drudis.2022.05.024_b0320","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.mam.2012.04.005","article-title":"Understanding age-related macular degeneration (AMD): relationships between the photoreceptor\/retinal pigment epithelium\/Bruch\u2019s membrane\/choriocapillaris complex","volume":"33","author":"Bhutto","year":"2012","journal-title":"Mol Aspects Med"},{"issue":"1","key":"10.1016\/j.drudis.2022.05.024_b0325","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.preteyeres.2009.08.003","article-title":"The dynamic nature of Bruch\u2019s membrane","volume":"29","author":"Booij","year":"2010","journal-title":"Progress Retinal Eye Res"},{"key":"10.1016\/j.drudis.2022.05.024_b0330","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.biomaterials.2018.03.034","article-title":"Hyaluronic acid coated albumin nanoparticles for targeted peptide delivery in the treatment of retinal ischaemia","volume":"168","author":"Di","year":"2018","journal-title":"Biomaterials"},{"key":"10.1016\/j.drudis.2022.05.024_b0335","doi-asserted-by":"crossref","first-page":"199","DOI":"10.3389\/fbioe.2018.00199","article-title":"Rheological Properties and Age-Related Changes of the Human Vitreous Humor","volume":"6","author":"Tram","year":"2018","journal-title":"Front Bioeng Biotechnol"},{"issue":"1","key":"10.1016\/j.drudis.2022.05.024_b0340","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.addr.2012.04.010","article-title":"Nanoparticles in drug delivery: Past, present and future","volume":"65","author":"Couvreur","year":"2013","journal-title":"Adv Drug Deliv Rev"},{"issue":"8","key":"10.1016\/j.drudis.2022.05.024_b0345","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1016\/j.drudis.2019.05.005","article-title":"Intravitreal nanoparticles for retinal delivery","volume":"24","author":"Huang","year":"2019","journal-title":"Drug Discovery Today"},{"issue":"2","key":"10.1016\/j.drudis.2022.05.024_b0350","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s11095-008-9745-6","article-title":"Investigating the movement of intravitreal human serum albumin nanoparticles in the vitreous and retina","volume":"26","author":"Kim","year":"2009","journal-title":"Pharm Res"},{"key":"10.1016\/j.drudis.2022.05.024_b0355","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.jconrel.2020.10.028","article-title":"Ocular barriers to retinal delivery of intravitreal liposomes: Impact of vitreoretinal interface","volume":"328","author":"Tavakoli","year":"2020","journal-title":"J Controll Release : Off J Controll Release Soc"},{"issue":"1","key":"10.1016\/j.drudis.2022.05.024_b0360","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jconrel.2013.01.018","article-title":"Nanoparticle diffusion in, and microrheology of, the bovine vitreous ex vivo","volume":"167","author":"Xu","year":"2013","journal-title":"J Controll Release : Off J Controll Release Soc"},{"issue":"10","key":"10.1016\/j.drudis.2022.05.024_b0365","first-page":"1377","article-title":"Zonulae adherentes pore size in the external limiting membrane of the rabbit retina","volume":"26","author":"Bunt-Milam","year":"1985","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"5","key":"10.1016\/j.drudis.2022.05.024_b0370","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1080\/02713683.2019.1565890","article-title":"Morphology and Composition of the Inner Limiting Membrane: Species-Specific Variations and Relevance toward Drug Delivery Research","volume":"44","author":"Peynshaert","year":"2019","journal-title":"Curr Eye Res"},{"key":"10.1016\/j.drudis.2022.05.024_b0375","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.2147\/IJN.S157000","article-title":"DNA nanoparticles are safe and nontoxic in non-human primate eyes","volume":"13","author":"Kelley","year":"2018","journal-title":"Int J Nanomed"},{"key":"10.1016\/j.drudis.2022.05.024_b0380","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.addr.2017.09.007","article-title":"In vitro and ex vivo models to study drug delivery barriers in the posterior segment of the eye","volume":"126","author":"Peynshaert","year":"2018","journal-title":"Adv Drug Deliv Rev"},{"issue":"5","key":"10.1016\/j.drudis.2022.05.024_b0385","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1002\/glia.22477","article-title":"New functions of M\u00fcller cells","volume":"61","author":"Reichenbach","year":"2013","journal-title":"Glia"},{"issue":"4","key":"10.1016\/j.drudis.2022.05.024_b0390","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S0042-6989(01)00185-7","article-title":"Immunobiology and privilege of neuronal retina and pigment epithelium transplants","volume":"42","author":"Streilein","year":"2002","journal-title":"Vision Res"},{"issue":"10","key":"10.1016\/j.drudis.2022.05.024_b0395","doi-asserted-by":"crossref","first-page":"e0241006","DOI":"10.1371\/journal.pone.0241006","article-title":"The effects of PEGylation on LNP based mRNA delivery to the eye","volume":"15","author":"Ryals","year":"2020","journal-title":"PLoS ONE"},{"issue":"8","key":"10.1016\/j.drudis.2022.05.024_b0400","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1093\/hmg\/ddt013","article-title":"S\/MAR-containing DNA nanoparticles promote persistent RPE gene expression and improvement in RPE65-associated LCA","volume":"22","author":"Koirala","year":"2013","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.drudis.2022.05.024_b0405","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/978-1-4614-3209-8_90","article-title":"Gene therapy for Stargardt disease associated with ABCA4 gene","volume":"801","author":"Han","year":"2014","journal-title":"Adv Exp Med Biol"},{"issue":"8","key":"10.1016\/j.drudis.2022.05.024_b0410","doi-asserted-by":"crossref","first-page":"3562","DOI":"10.1167\/iovs.02-1068","article-title":"Ocular Drug Delivery Targeting the Retina and Retinal Pigment Epithelium Using Polylactide Nanoparticles","volume":"44","author":"Bourges","year":"2003","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.drudis.2022.05.024_b0415","doi-asserted-by":"crossref","first-page":"43092","DOI":"10.1038\/srep43092","article-title":"Magnetic nanoparticles: A strategy to target the choroidal layer in the posterior segment of the eye","volume":"7","author":"Giannaccini","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.drudis.2022.05.024_b0420","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jconrel.2017.02.013","article-title":"Differentially cleaving peptides as a strategy for controlled drug release in human retinal pigment epithelial cells","volume":"251","author":"Bhattacharya","year":"2017","journal-title":"J Controll Release : Off J Controll Release Soc"},{"issue":"7","key":"10.1016\/j.drudis.2022.05.024_b0425","doi-asserted-by":"crossref","DOI":"10.3390\/cells9071617","article-title":"Nanoceria Particles Are an Eligible Candidate to Prevent Age-Related Macular Degeneration by Inhibiting Retinal Pigment Epithelium Cell Death and Autophagy Alterations","volume":"9","author":"Tisi","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.drudis.2022.05.024_b0430","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/978-3-030-27378-1_21","article-title":"Temporal Distribution Patterns of Alexa Fluor 647-Conjugated CeNPs in the Mouse Retina After a Single Intravitreal Injection","volume":"1185","author":"Wong","year":"2019","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.drudis.2022.05.024_b0435","doi-asserted-by":"crossref","first-page":"108169","DOI":"10.1016\/j.exer.2020.108169","article-title":"Cerium oxide nanoparticles reduce the accumulation of autofluorescent deposits in light-induced retinal degeneration: Insights for age-related macular degeneration","volume":"199","author":"Tisi","year":"2020","journal-title":"Exp Eye Res"},{"issue":"7","key":"10.1016\/j.drudis.2022.05.024_b0440","doi-asserted-by":"crossref","first-page":"4789","DOI":"10.1167\/iovs.10-5891","article-title":"A lipid nanoparticle system improves siRNA efficacy in RPE cells and a laser-induced murine CNV model","volume":"52","author":"Liu","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"7","key":"10.1016\/j.drudis.2022.05.024_b0445","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1016\/j.biomaterials.2010.11.030","article-title":"The inhibition of retinal neovascularization by gold nanoparticles via suppression of VEGFR-2 activation","volume":"32","author":"Kim","year":"2011","journal-title":"Biomaterials"},{"issue":"2","key":"10.1016\/j.drudis.2022.05.024_b0450","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ejpb.2012.09.010","article-title":"Low molecular weight oligochitosans for non-viral retinal gene therapy","volume":"83","author":"Puras","year":"2013","journal-title":"Eur J Pharmaceut Biopharmaceut : Off J Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik eV"},{"issue":"1","key":"10.1016\/j.drudis.2022.05.024_b0455","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.3390\/ijms15011590","article-title":"Magnetic nanoparticles as intraocular drug delivery system to target retinal pigmented epithelium (RPE)","volume":"15","author":"Giannaccini","year":"2014","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10.1016\/j.drudis.2022.05.024_b0460","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.jconrel.2009.10.031","article-title":"Nanoparticle-integrin antagonist C16Y peptide treatment of choroidal neovascularization in rats","volume":"142","author":"Kim","year":"2010","journal-title":"J Controlled Release : Off J Controll Release Soc"},{"issue":"24","key":"10.1016\/j.drudis.2022.05.024_b0465","doi-asserted-by":"crossref","first-page":"5978","DOI":"10.1016\/j.biomaterials.2013.04.035","article-title":"Hyaluronan-modified core-shell liponanoparticles targeting CD44-positive retinal pigment epithelium cells via intravitreal injection","volume":"34","author":"Gan","year":"2013","journal-title":"Biomaterials"},{"key":"10.1016\/j.drudis.2022.05.024_b0470","doi-asserted-by":"crossref","first-page":"120226","DOI":"10.1016\/j.ijpharm.2021.120226","article-title":"Safety assessment of polymeric micelles as an ophthalmic drug delivery system for intravitreal administration of dasatinib","volume":"596","author":"Li","year":"2021","journal-title":"Int J Pharm"},{"issue":"4","key":"10.1016\/j.drudis.2022.05.024_b0475","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1089\/hum.2011.115","article-title":"Dextran and protamine-based solid lipid nanoparticles as potential vectors for the treatment of X-linked juvenile retinoschisis","volume":"23","author":"Delgado","year":"2012","journal-title":"Hum Gene Ther"},{"issue":"1","key":"10.1016\/j.drudis.2022.05.024_b0480","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14010012","article-title":"Pharmacokinetics of Pullulan-Dexamethasone Conjugates in Retinal Drug Delivery","volume":"14","author":"Kickov\u00e1","year":"2021","journal-title":"Pharmaceutics"},{"issue":"11","key":"10.1016\/j.drudis.2022.05.024_b0485","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1016\/j.addr.2006.07.027","article-title":"Challenges and obstacles of ocular pharmacokinetics and drug delivery","volume":"58","author":"Urtti","year":"2006","journal-title":"Adv Drug Deliv Rev"},{"issue":"9","key":"10.1016\/j.drudis.2022.05.024_b0490","doi-asserted-by":"crossref","first-page":"4148","DOI":"10.1091\/mbc.e04-01-0058","article-title":"The basolateral targeting signal of CD147 (EMMPRIN) consists of a single leucine and is not recognized by retinal pigment epithelium","volume":"15","author":"Deora","year":"2004","journal-title":"Mol Biol Cell"},{"issue":"2","key":"10.1016\/j.drudis.2022.05.024_b0495","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.exer.2005.10.034","article-title":"Glucose utilization by the retinal pigment epithelium: evidence for rapid uptake and storage in glycogen, followed by glycogen utilization","volume":"83","author":"Des Senanayake","year":"2006","journal-title":"Exp Eye Res"},{"issue":"7","key":"10.1016\/j.drudis.2022.05.024_b0500","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1111\/jcmm.12070","article-title":"Directional protein secretion by the retinal pigment epithelium: roles in retinal health and the development of age-related macular degeneration","volume":"17","author":"Kay","year":"2013","journal-title":"J Cell Mol Med"},{"issue":"5","key":"10.1016\/j.drudis.2022.05.024_b0505","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/gt.2008.185","article-title":"Intravenous transferrin, RGD peptide and dual-targeted nanoparticles enhance anti-VEGF intraceptor gene delivery to laser-induced CNV","volume":"16","author":"Singh","year":"2009","journal-title":"Gene Ther"},{"issue":"8","key":"10.1016\/j.drudis.2022.05.024_b0510","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1136\/bjo.2008.144006","article-title":"Expression of reverse cholesterol transport proteins ATP-binding cassette A1 (ABCA1) and scavenger receptor BI (SR-BI) in the retina and retinal pigment epithelium","volume":"93","author":"Duncan","year":"2009","journal-title":"British J Ophthalmol"},{"issue":"4","key":"10.1016\/j.drudis.2022.05.024_b0515","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1167\/iovs.15-17934","article-title":"Albumen Transport to Bruch\u2019s Membrane and RPE by Choriocapillaris Caveolae","volume":"57","author":"Nakanishi","year":"2016","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"6","key":"10.1016\/j.drudis.2022.05.024_b0520","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/j.devcel.2012.11.003","article-title":"The diaphragms of fenestrated endothelia: gatekeepers of vascular permeability and blood composition","volume":"23","author":"Stan","year":"2012","journal-title":"Dev Cell"},{"issue":"1","key":"10.1016\/j.drudis.2022.05.024_b0525","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jconrel.2010.08.028","article-title":"Barrier analysis of periocular drug delivery to the posterior segment","volume":"148","author":"Ranta","year":"2010","journal-title":"J Control Release"},{"key":"10.1016\/j.drudis.2022.05.024_b0530","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jconrel.2015.10.033","article-title":"Multivalent nanoparticles bind the retinal and choroidal vasculature","volume":"220","author":"Henning","year":"2015","journal-title":"J Control Release"},{"issue":"50","key":"10.1016\/j.drudis.2022.05.024_b0535","doi-asserted-by":"crossref","first-page":"505101","DOI":"10.1088\/0957-4484\/20\/50\/505101","article-title":"Intravenously administered gold nanoparticles pass through the blood-retinal barrier depending on the particle size, and induce no retinal toxicity","volume":"20","author":"Kim","year":"2009","journal-title":"Nanotechnology"},{"issue":"8","key":"10.1016\/j.drudis.2022.05.024_b0540","doi-asserted-by":"crossref","first-page":"4413","DOI":"10.1167\/iovs.14-16250","article-title":"Systemic and Intravitreal Delivery of Dendrimers to Activated Microglia\/Macrophage in Ischemia\/Reperfusion Mouse Retina","volume":"56","author":"Kambhampati","year":"2015","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.drudis.2022.05.024_b0545","doi-asserted-by":"crossref","first-page":"102205","DOI":"10.1016\/j.nano.2020.102205","article-title":"Inhibition of choroidal neovascularization by systemic delivery of gold nanoparticles","volume":"28","author":"Singh","year":"2020","journal-title":"Nanomed Nanotechnol Biol Med"},{"issue":"9","key":"10.1016\/j.drudis.2022.05.024_b0550","first-page":"3075","article-title":"Widespread expression of an exogenous gene in the eye after intravenous administration","volume":"43","author":"Zhu","year":"2002","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.drudis.2022.05.024_b0555","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.jconrel.2021.05.035","article-title":"Systemic dendrimer nanotherapies for targeted suppression of choroidal inflammation and neovascularization in age-related macular degeneration","volume":"335","author":"Kambhampati","year":"2021","journal-title":"J Controll Release : Off J Controll Release Soc"},{"key":"10.1016\/j.drudis.2022.05.024_b0560","first-page":"465","article-title":"Organ-specific gene expression in the rhesus monkey eye following intravenous non-viral gene transfer","volume":"9","author":"Zhang","year":"2003","journal-title":"Mol Vision"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S135964462200215X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S135964462200215X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T12:59:17Z","timestamp":1761224357000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S135964462200215X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":112,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S135964462200215X"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2022.05.024","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeted drug delivery to the retinal pigment epithelium: Untapped therapeutic potential for retinal diseases","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2022.05.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}